GlassScriptPhysician profile
Elliot M Paul
NPI 1962441113
$10,028.60
in general payments reported to CMS, 2019-2025
33 companies · $3,691 in 2025
The $3,691 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $590 · 2021: $760 · 2022: $941 · 2023: $2,348 · 2024: $905 · 2025: $3,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907 · Consulting Fee: $2,783 · Honoraria: $975 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.54 |
| Consulting Fee | $2,783.00 |
| Honoraria | $975.00 |
| Education | $279.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $3,076.14 | 2019-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $1,155.53 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $1,012.89 | 2019-2025 | Erleada, Akeega |
| Ambu A/S | $975.00 | 2023 | |
| Astellas Pharma US INC | $769.44 | 2019-2024 | Xtandi, Myrbetriq |
| Urovant Sciences INC | $482.03 | 2021-2022 | |
| Neotract INC. | $454.51 | 2019-2020 | |
| Myovant Sciences INC. | $291.29 | 2021-2022 | |
| Boston Scientific Corporation | $286.22 | 2019-2023 | |
| Pfizer INC. | $173.84 | 2019-2025 | |
| Tolmar, INC. | $137.21 | 2023-2025 | Jatenzo |
| Progenics Pharmaceuticals, INC. | $124.34 | 2023 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $109.45 | 2019-2023 | |
| Teleflex LLC | $106.66 | 2021-2025 | Urolift |
| Urogen Pharma, INC. | $106.52 | 2022-2023 | Jelmyto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Comsort, INC | $100.00 | 2019 | |
| Dendreon Pharmaceuticals LLC | $92.54 | 2019-2025 | Provenge |
| Olympus America INC. | $82.23 | 2022-2025 | Itind System |
| Verity Pharmaceuticals INC. | $70.46 | 2024-2025 | Trelstar |
| Calyxo, INC. | $70.23 | 2023-2025 | Cvac Aspiration System |
| Amgen INC. | $55.42 | 2019-2021 | |
| Accord Healthcare, INC. | $42.46 | 2022-2023 | |
| Myriad Genetic Laboratories, INC. | $39.98 | 2025 | Prolaris |
| Coloplast Corp | $30.50 | 2019 | |
| Civco Medical Instruments | $29.04 | 2025 | |
| Immunitybio, INC. | $28.38 | 2025 | |
| Blue Earth Diagnostics | $26.49 | 2019 | |
| Clarus Therapeutics INC. | $21.21 | 2021 | |
| Axonics, INC. | $17.53 | 2024 | Bulkamid |
| Abbvie INC. | $15.94 | 2024 | |
| Karl Storz Endoscopy-America | $15.37 | 2019 | |
| Endo Pharmaceuticals INC. | $15.24 | 2019 | |
| Allergan, INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.